OGT, Mergen Settle Microarray Patent-Infringement Suit | GenomeWeb

NEW YORK, Jan. 20 (GenomeWeb News) - Mergen and Oxford Gene Technology agreed on Jan. 13 to settle the patent-infringement litigation between them, according to Mergen spokesperson Jamie Love.

Under the terms of the deal, Sunnyvale, Calif.-based Mergen has purchased a license from Oxford, UK-based OGT allowing the company to manufacture and sell microarrays for investigating gene expression. Mergen has also dropped a countersuit as part of the deal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.